Analyst Kyle Mikson CFA of Canaccord Genuity maintained a Hold rating on Akoya Biosciences (AKYA – Research Report), retaining the price target of $3.50.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Kyle Mikson CFA has given his Hold rating due to a combination of factors impacting Akoya Biosciences. The company’s recent financial performance showed a decline in instrument revenue due to capital purchasing constraints, although overall revenue was in line with expectations. Despite a sequential decrease in cash burn and improved gross margins driven by operational efficiency, Akoya did not provide 2025 financial guidance due to its pending acquisition by Quanterix.
Furthermore, uncertainties surrounding NIH funding could negatively affect Akoya’s academic research business. While the merger with Quanterix presents a value proposition, investor skepticism about the deal’s synergies and the potential challenges in realizing near- to medium-term benefits contribute to the Hold rating. The anticipated muted share price performance until the shareholder and merger vote further supports this cautious stance.